Beijing Hotgen Biotech Co. Ltd. Class ASSE: 688068

"BEIJING HOTGEN BIOTECH CO., LTD."Announcement on Voluntary Disclosure of Completion of First Subject Enrollment and Dosing in the Phase I/IIa Clinical Trial of Subsidiary's Innovative Drug SGT003

Sep 15, 2026 · Issued by Beijing Hotgen Biotech Co. Ltd. Class A via Shanghai Stock Exchange

Filed with SSE · Sep 15, 2026

Announcement on Voluntary Disclosure of Completion of First Subject Enrollment and Dosing in the Phase I/IIa Clinical Trial of Subsidiary's Innovative Drug SGT003

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Company analysis

Earlier from Beijing Hotgen Biotech Co. Ltd. Class A

"BEIJING HOTGEN BIOTECH CO., LTD."Announcement on Change of Registered Capital, Amendment to the Articles of Association and Filing of Industrial and Commercial Registration ChangesAug 27
"BEIJING HOTGEN BIOTECH CO., LTD."Announcement on Implementation Results of Share Repurchase and Share ChangesAug 8
"BEIJING HOTGEN BIOTECH CO., LTD."Announcement on Adjustment of Core Technical PersonnelAug 4
"BEIJING HOTGEN BIOTECH CO., LTD."Announcement on Voluntary Disclosure of Obtaining "Drug Clinical Trial Approval" for New Indication of Subsidiary's Innovative Drug SGC001 InjectionAug 1

All Beijing Hotgen Biotech Co. Ltd. Class A news releases